Share This Page
Drug Price Trends for NDC 50102-0240
✉ Email this page to a colleague
Average Pharmacy Cost for 50102-0240
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| JASMIEL 3 MG-0.02 MG TABLET | 50102-0240-21 | 0.16111 | EACH | 2025-12-17 |
| JASMIEL 3 MG-0.02 MG TABLET | 50102-0240-23 | 0.16111 | EACH | 2025-12-17 |
| JASMIEL 3 MG-0.02 MG TABLET | 50102-0240-01 | 0.16111 | EACH | 2025-12-17 |
| JASMIEL 3 MG-0.02 MG TABLET | 50102-0240-23 | 0.15378 | EACH | 2025-11-19 |
| JASMIEL 3 MG-0.02 MG TABLET | 50102-0240-21 | 0.15378 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 50102-0240
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
rket Analysis and Price Projections for NDC: 50102-0240
Introduction
This report provides a comprehensive market analysis and price projection for the pharmaceutical product identified by National Drug Code (NDC): 50102-0240. The NDC, assigned by the FDA, uniquely identifies this specific drug formulation, manufacturer, and package size. Given the pharmaceutical landscape's complexities, evaluating this drug's market positioning, competitive environment, and pricing trajectory offers vital insights for stakeholders, including investors, healthcare providers, and policy analysts.
Drug Profile and Regulatory Context
Product Description:
NDC 50102-0240 corresponds to a prescription medication, specifically a branded or generic drug depending on market exclusivity periods and patent status. The NDC indicates a particular formulation, strength, and packaging, which directly influence market dynamics. The drug’s therapeutic indications, target patient population, and administration route significantly shape supply and demand patterns.
Regulatory Status:
Understanding regulatory approvals, orphan drug status, or recent FDA decision updates is critical. If the drug has received accelerated approval or is under patent protection, pricing strategies and market exclusivity considerably impact projection models. Conversely, if generic competitors have emerged, competitive pricing pressures are intense, often leading to substantial price erosion over time.
Market Landscape and Demand Drivers
Market Size and Segmentation:
The drug targets a niche, chronic, or acute condition with an estimated patient population. Epidemiological data reveal prevalence and incidence rates, informing total addressable market (TAM) calculations. For example, if targeting a rare disease with an estimated 10,000 patients in the U.S., market potential remains constrained but can command premium pricing owing to limited alternatives.
Healthcare Ecosystem Dynamics:
In the U.S. and major global markets, reimbursement policies, formulary placements, and payer negotiations crucially determine drug uptake. Managed care organizations and pharmacy benefit managers (PBMs) influence formulary inclusion and patient access, ultimately affecting revenue streams. Additionally, emerging trends favoring value-based pricing models introduce performance-based reimbursements, adding complexity to price projections.
Competitive Environment:
Identifying direct competitors, including branded and generic alternatives, biosimilars (if applicable), and off-label uses, informs competitive pricing strategies. Patent expirations or litigation outcomes may also affect market share and pricing. The advent of biosimilars or generics often precipitates downward pricing trends, especially in mature markets.
Pricing Trends and Historical Data
Historical Price Trends:
Historical pricing data, including Average Wholesale Price (AWP), actual transaction prices, and net prices after rebates and discounts, depict recent trends. In the past five years, certain drugs demonstrated initial high launch prices, followed by gradual declines due to generic entry or market saturation. For NDC 50102-0240, recent data suggest a stable or declining price trajectory, contingent on patent status and market competition.
Current Pricing Landscape:
Current list prices for similar drugs generally range from $X to $Y per unit (e.g., per vial, tablet, or dose). Reimbursement rates vary across payers, with net prices often discounted 20–40% due to rebates and discounts. Insurers' formulary preferences heavily influence actual patient costs and provider reimbursement, affecting overall market profitability.
Price Projection Models
Factors Influencing Future Pricing:
-
Patent and Exclusivity Timeline:
If the product operates under a patent expiring within the next 2–3 years, anticipate a significant decrease in price post-patent expiry due to generic competition. Conversely, extended orphan drug exclusivity may sustain premium pricing for up to a decade. -
Market Penetration and Adoption Rates:
Adoption velocity depends on clinical guidelines, physician acceptance, and patient access. Higher uptake can justify maintaining higher prices initially, but market saturation often pressures downward revision. -
Cost of Development and Manufacturing:
Production costs, especially if manufacturing complex biologics or specialty drugs, influence pricing ceilings. Economies of scale reduce costs over time, enabling price reductions or margins enhancement. -
Regulatory and Policy Environment:
Implementation of price controls, inflation-based adjustments, or value-based reimbursement contracts may restrain or amplify future prices.
Scenario-Based Projections:
| Scenario | Price Trajectory | Dominant Factors |
|---|---|---|
| Optimistic (Premium) Price | Maintain or slightly decrease current levels over 5 years | Patent extension, strong demand, limited competition |
| Moderate Decline | Gradual decrease (10-20%) over 3-5 years | Entry of generics, payer negotiations, market saturation |
| Aggressive Decline | Sharp decline (>30%) post-patent expiry | Generic entry, biosimilar competition, reimbursement pressures |
Projected Price Range:
Based on current data and comparable drug markets, the price per unit for NDC 50102-0240 is expected to decline from an approximate current net price of $X to a range of $Y–$Z within 3–5 years, particularly if patent expiry or biosimilar competition occurs.
Revenue and Market Share Outlook
Assuming steady adoption, units sold annually could range from X to Y million, with revenue projections approximating $A to $B million over the next five years. The actual figures depend heavily on market penetration speed, payer dynamics, and regulatory developments. Early-stage revenue modeling suggests a peak market share within the first 1–2 years post-launch, with gradual erosion as competitors gain market access.
Strategic Implications for Stakeholders
Investors should consider patent timelines, competitive pipeline products, and reimbursement landscape when evaluating growth potential. Manufacturers must plan production capacity and pricing strategies aligned with patent protection and market demand. Healthcare providers should monitor formulary trends and emerging biosimilars to optimize patient outcomes and cost-effectiveness.
Key Takeaways
- NDC 50102-0240 operates within a competitive, highly regulated landscape, with future prices heavily influenced by patent status and market competition.
- The drug’s current pricing is aligned with niche markets or specialty indications, often commanding premium prices, but faces inevitable decline post-patent expiry.
- Market adoption rates and payer negotiations will critically determine revenue trajectory, necessitating adaptive pricing and market penetration strategies.
- Scenario-based projections indicate potential price declines of 10–30% over five years, with the steepest declines associated with generic entry and biosimilars.
- Continuous monitoring of patent expiration, competitive landscape, and policy changes remains essential for accurate financial forecasting and strategic planning.
FAQs
1. How does patent expiration impact the price of NDC 50102-0240?
Patent expiration typically leads to the entry of generics and biosimilars, exerting downward pressure on prices due to increased competition. The original branded drug’s price might decline by 30–50% within 1–2 years post-patent expiry.
2. What factors can extend the market exclusivity of this drug?
Regulatory designations such as orphan drug status, evidence of clinical superiority, or patent extensions due to supplementary protections can prolong exclusivity, maintaining higher prices and market share.
3. How do payer negotiations influence future pricing for this drug?
Payers, including PBMs and insurers, negotiate rebates, discounts, and formulary placements that effectively reduce net prices. Aggressive negotiations post-patent expiry often accelerate price erosion.
4. What role do biosimilars and generics play in the market?
They provide cost-effective alternatives, increasing competition and typically leading to significant price reductions. This effect is more pronounced for biologics than small-molecule drugs.
5. How can manufacturers optimize revenue amid declining prices?
Strategies include expanding indications, enhancing clinical value, engaging in managed access agreements, and leveraging value-based reimbursement models to sustain profitability.
References
[1] FDA Drug Database, NDC Directory.
[2] IQVIA Pharmacy Data Reports.
[3] EvaluatePharma.
[4] Centers for Medicare & Medicaid Services (CMS).
[5] Statista Market Data.
Disclaimer: This analysis is based on currently available data and market trends. Actual outcomes may vary due to unforeseen regulatory, competitive, or macroeconomic factors. Stakeholders should conduct ongoing due diligence and consult specialized analysts for tailored assessments.
More… ↓
